關鍵數據
33.780今開
33.780最高
507.25K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.78%換手率
33.880昨收
32.000最低
13.20M成交額
虧損本益比靜
6.80市淨率
0.00%股息率 TTM
-66.38%ROA
33.33052週最高
1.40量比
-100.88M淨利潤
65.21M總股本
-2.3543每股盈餘TTM
-2.35Beta
-73.02%ROE
15.51052週最低
5.25%振幅
--毛利率
2.27B總市值
0.56回報/風險
3.53%風險率
Pharvaris NV新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Pharvaris NV簡介
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
公司代碼PHVS
公司Pharvaris NV
CEOModig (Berndt B.A.E)
網址https://pharvaris.com/
公司股東
常見問題
Pharvaris NV(PHVS)的當前股價是多少?
Pharvaris NV(PHVS)的當前股價是 32.62。
Pharvaris NV股票的52週最高點是多少?
Pharvaris NV股票的52週最高點是33.33。
Pharvaris NV股票的52週最低點是多少?
Pharvaris NV股票的52週最低點是15.51。
現在Pharvaris NV(PHVS)的股票是買入、持有還是賣出?
根據分析師評級,Pharvaris NV(PHVS)的總體評級為買入,目標價格為47.60。
Pharvaris NV(PHVS)股票的每股收益(EPS TTM)是多少
Pharvaris NV(PHVS)股票的每股收益(EPS TTM)是-3.49。